Poly-cystic Ovarian Syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: The intervention will be performed with weight loss diet (reduction of 300-500 kcal per day of energy required based on the adjusted ideal body weight) and three 1
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Diagnosis of polycystic ovary syndrome based on Rotterdam criteria for at least two of the following factors: 1. Oligomnorrhea or amenorrhea. 2. Biochemical or clinical symptoms increased levels of androgens in the blood.3- Having polycystic ovaries in ultrasound Women with age range between 18-45 year Body mass index more than 30 kg/m2 Voluntary participation in the project
Exclusion criteria
Exclusion criteria: Pregnancy and lactation Illnesses such as autoimmune, gastrointestinal, liver, thyroid and unstable cardiovascular diseases, severe depression, mental diseases, severe respiratory diseases (asthma and chronic bronchitis) Take any vitamin and mineral supplements Allergies to cardamom, cardamom tea and cardamom products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reducing of weight among obese women with polycystic ovary syndrome. Timepoint: Measurement of weight before intervention and 12 week after intervention. Method of measurement: Weight measurement will be performed using the Inbody 770 with minimal clothing.;Reducing of waist circumference among obese women with polycystic ovary syndrome. Timepoint: Measurement of waist circumference before intervention and 12 week after intervention. Method of measurement: Waist circumference measurement will be performed using a flexible tape between the last rib and the top of the iliac crest in exhalation.;Improvement of blood pressure among obese women with polycystic ovary syndrome. Timepoint: Measurement of blood pressure before intervention and 12 week after intervention. Method of measurement: Blood pressure will be measured using a digital arm sphygmomanometer.;Improvement of insulin level. Timepoint: Measurement of insulin level before intervention and 12 week after intervention. Method of measurement: Insulin level will be measured by ELISA method.;Improvement of fasting blood sugar. Timepoint: Measurement of fasting blood sugar before intervention and 12 week after intervention. Method of measurement: Fasting blood sugar was measured by Glucose oxidase method.;Improvement of lipid profile. Timepoint: Measurement of lipid profile before intervention and 12 week after intervention. Method of measurement: Lipid profile will be measured by enzymatic kits (Pars Azmoon, Iran).;Improvement of inflammatory status. Timepoint: Measurement of C- reactive protein before intervention and 12 week after intervention. Method of measurement: Measurement of C- reactive protein will be performed by Highly sensitive CRP assay method.;Reducing of obesity and diabetes gene expression. Timepoint: Measurement of obesity and diabetes gene expression before intervention and 12 week after intervention. Method of measurement: The expression of obesity and diabetes genes will be determined by Real T | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShima Moradi
Kermanshah University of Medical Sciences
Outcome results
None listed